Other content in this Stream
Liminal BioSciences announces scientific presentations at upcoming Keystone Symposia
LMNL announced the Company and its collaborators will present scientific findings at two upcoming Keystone Symposia
Liminal BioSciences announces upcoming investor presentation at BIO CEO & investor conference
Members of the management team will provide a business overview and update at the BIO CEO & Investor Conference taking place February 10-11, 2020 in New York, USA.
Liminal BioSciences outlines corporate priorities for 2020
Quarterly Report Q3 2019
Quarterly Report 2019 Q2
Quarterly Report 2019 Q1
Nasdaq Statement of Corporate Governance Differences
Board of Directors Charter 2019
Code of Ethics and Business Conduct 2019
Position Description Lead Independent Director 2019
HR & Corporate Governance Committee Charter 2019
Rare Disease: Alström Syndrome
John and Kay Parkinson are the parents of two children who were diagnosed very late with the ultra-rare disease Alström Syndrome.
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment